The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea in adults with ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA-mutated, HER2-negative breast cancer who received one year of the oral ...

Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival (PFS) in untreated chronic lymphocytic leukemia (CLL). With 77% of patients ...

Merck has announced a significant milestone in the treatment of advanced epithelial ovarian cancer. The Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) plus chemotherapy, ...

We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the groundbreaking advancements of GIGA-2339, the first recombinant polyclonal drug ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Backed by robust data from the TROPION-Lung05 ...

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven biological research, in a strategic equity partnership aimed at ...